Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  prexasertib
Find trials that include:  Any drugs shown
Results 1-7 of 7 for your search:
Start Over
Prexasertib in Treating Patients with BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple-Negative Breast Cancer, or High Grade Ovarian Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0156, NCI-2014-02304, 140156, 342996, P131428, NCT02203513
Prexasertib in Treating Patients with Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-281, NCI-2016-01564, NCT02873975
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15295, NCI-2014-01348, I4D-MC-JTJF, NCT02124148
A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16016, NCI-2015-02234, 2015-001215-12, I4D-MC-JTJI, NCT02555644
Prexasertib, Cytarabine, and Fludarabine Phosphate in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0665, NCI-2016-00225, NCT02649764
Prexasertib in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 12 months to 21 years
Trial IDs: ADVL1515, NCI-2016-00643, NCT02808650
Prexasertib and Olaparib in Treating Patients with Metastatic or Unresectable Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-573, NCI-2017-00488, NCT03057145
Start Over